Product Images Tecartus
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 10 images provide visual information about the product associated with Tecartus NDC 71287-220 by Kite Pharma, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
WA brexucabtagene autoleucel is a product manufactured by Kite Pharma, Inc that comes in a sterile bag for infusion with a dose amounting to a maximum of 2 x 10® autologous anti-CD19 CAR T cells in approximately 68 mL suspension containing 5% DMSO USP. The product should not be irradiated and should be shipped and stored in vapor phase of liquid nitrogen <-150°C. It is preservative-free but is manufactured with gentamicin. The full prescribing information and administration instructions can be found in the package insert.*
This is a description of a medication known as brexucabtagene autoleucel, with the brand name TECARTUS®. The drug comes in a sterile bag for infusion and contains a maximum of 2x10 autologous anti-CD19 CAR T cells in approximately 68 ml suspension containing 5% DMSO USP. The drug should be thawed carefully, and the instructions for administering it can be found in the package insert. The drug must be shipped and stored in the vapour phase of liquid nitrogen at a temperature of <-150°C. The manufacturer is Kite Pharma, Inc. Their contact number is 1-844-454-KITE. The medication has not been evaluated for infectious substances but is free of preservatives.*
This is a description of information related to a medical treatment, specifically the product "brexucabtagene autoleucel", which may require verification. There are some identification details, such as Lot and Kite Patient IDs, Expiration Date, First and Last Name, DOB and Hospital Patient ID. However, much of the text appears to be incomplete or possibly corrupted during the process, so the context of the information cannot be fully evaluated.*
This text seems to be a verification report for a medicine called "brexucabtagene autoleucel". It mentions a patient ID and a product ID called "TECARTUS". It also includes some lot number and date of expiration details. However, some of the text appears to be cut off, making it difficult to deduce the complete information.*
This is a description of two medical therapies used for autologous and intravenous use to treat certain medical conditions. The two therapies are called bresucabiagene and toleucel. The description provides instructions for use, including dosage and administration. The therapy comes in a sterile bag, and should be gently mixed and thawed before use. Gentle handling of the product is recommended, and it is advised not to use irradiation on the product. The product is manufactured with gentamicin, and has not been evaluated for infectious substances. It is preservative-free and must be stored in temperatures below -150°C. The manufacturer of the therapy is Kite Pharma, Inc, with a phone number provided. There is no U.S. standard of potency available for the product.*
Brexucabtagene autoleucel is a medication for autologous and intravenous use. It is a sterile bag for infusion containing a maximum of 1 x 10° autologous anti-CD19 CAR T cells in approximately 68 mL suspension with 5% DMSO USP. The contents of the bag need to be gently mixed while thawing, and the leukodepleting filter should not be used. Additionally, it does not contain any preservatives and should not be irradiated. Kite Pharma, Inc. manufactures the medication and is located in Santa Monica, California. For full prescribing information and administration instructions, please refer to the package insert. The medication has not been evaluated for infectious substances.*
This is a patient record with details such as patient's Lot Number, Kite Patient ID, Expiration Date, First Name, Middle Initial, Last Name, Date of Birth and Hospital Patient ID. The text also contains an unrecognizable character.*
This text contains information about a patient's ID, the product name brexucabtagene autoleucel, and other details such as lot number, expiration date, name, date of birth, and hospital patient ID. The text also has a call to action to confirm the patient ID before infusion.*
brexucabtagene autoleucel is a treatment offered by Kite Pharma, Inc. under the name TECARTUS®. The text also includes a site code (FXX), a cell order number (123456789), a LOT number (123456789-01), and contact information for Kite Pharma's office in Santa Monica, CA. The text concludes with an AS-02536 identifier.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.